XM02 is superior to placebo and equivalent to Neupogen™ in reducing the duration of severe neutropenia and the incidence of febrile neutropenia in cycle 1 in breast cancer patients receiving docetaxel/doxorubicin chemotherapyAuro del Giglio, Heinz Lubenau, Alexandru Eniu et al.|BMC Cancer|2008Cited by 105